A Phase II, Multi-Center Study to Evaluate the Efficacy and Safety of Volrustomig as Monotherapy or in Combination With Anti-cancer Agents in Participants With Advanced/Metastatic Solid Tumors

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT06535607

Title field or adapter rule

protocolSection.identificationModule.officialTitle

Ingested At

2026-04-25T22:28:09.319332+00:00

Published At

2026-03-24T00:00:00+00:00

Record Updated At

2026-03-24

Timestamp Basis

source retrieval time was not retained by the feed adapter

Date limitation

source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Sub-study 1 Cervical Cancer (Volrustomig Monotherapy)", "Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy)", "Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)", "Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)", "Sub-study 5 Unresectable Pleural Mesothelioma (Volrustomig Monotherapy)"]

protocolSection.statusModule.lastUpdatePostDateStruct.date

"2026-03-24"

protocolSection.identificationModule.nctId

"NCT06535607"

protocolSection.identificationModule.officialTitle

"A Phase II, Multi-Center Study to Evaluate the Efficacy and Safety of Volrustomig as Monotherapy or in Combination With Anti-cancer Agents in Participants With Advanced/Metastatic Solid Tumors"

protocolSection.statusModule.overallStatus

"RECRUITING"

protocolSection.designModule.phases

["PHASE2"]

protocolSection.statusModule.resultsFirstPostDateStruct.date

""

Study condition terms

• Sub-study 1 Cervical Cancer (Volrustomig Monotherapy) (protocolSection.conditionsModule.conditions)
• Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy) (protocolSection.conditionsModule.conditions)
• Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy) (protocolSection.conditionsModule.conditions)
• Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy) (protocolSection.conditionsModule.conditions)
• Sub-study 5 Unresectable Pleural Mesothelioma (Volrustomig Monotherapy) (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.